The lower omentin-1 values of SGA newborns compared to that of other newborns suggests that there is a relationship between omentin-1 values and low birth weight and fetal development. There was no study to compare with our findings, so omentin-1 levels in the SGA group were evaluated for the first time in our study. Decreased serum omentin-1 levels in patients with impaired glucose metabolism cause an insulin-induced glucose uptake into visceral adipocytes or other insulin-sensitive tissues (
8). Therefore, the influence of insulin decreases if there is an omentin-1 deficiency. It has been reported that the insulin secretion by the fetal pancreas regulates the fetal growth by maternal glucose concentrations (
15). Pancreatic agenesis, which causes the absence of fetal insulin secretion, leads to a decrease in body weight (
16). In animal models, hyperleptinemia and hyperinsulinaemia were seen in animals with leptin and insulin resistance. The growth retardation was reported to be the key element for the development of hyperphagia, obesity and hypertension (
17). Insulin is essential for growth and the lack of insulin causes weight loss and other complications. Lower levels of omentin-1 in newborns with SGA are likely to reduce insulin effects, thus leads to a decreased fetal growth and low birth weight (
12,
13).
It is well known that newborns with SGA bear the risk of obesity and an altered body composition in postnatal growt related to unfavorable intrauterine conditions. Decreased insulin secretion and increased insulin resistance cause the development of metabolic disease in adolescent and adult ages (
18). It was reported that patients with impaired glucose tolerance or type-2 diabetes mellitus had increased serum glucose levels and insulin levels as well as decreased omentin-1 levels compared to the normal population (
17). Omentin-1 levels were reported to be associated with an increase in serum glucose or insulin levels. Decreased levels of omentin-1 may increase insulin resistance and insulin levels (
11,
19,
20). It is not known whether there are other factors affecting omentin-1 levels and the low omentin-1 levels result in increasing glucose and insulin levels yet.
Kafalidis et al. evaluated the umbilical cord omentin-1 values of newborns with LGA and AGA and found that omentin-1 levels of newborns with LGA were significantly higher compared to newborns with AGA. However, they found that omentin-1 levels were significantly lower in vaginal deliveries compared to the control group (
2). The results of our study were not compared with those in this study, because omentin-1 levels were determined at different levels according to the birth pattern and gestational diabetes mellitus was reported in 16 of 61 mothers. Newborns with LGA have more adipose tissue and more released omentin-1. However, omentin values of newborns with LGA and AGA were statistically similar. Increased insulin secretions in newborns with LGA were likely to depress omentin-1 secretion. Insulin levels remain to be higher in newborns with LGA without an insulin resistance (
2). But, insulin values of newborns with SGA, LGA, and AGA were statistically similar. Other factors, such as a low-calorie diet, high glucose und insulin intake, might affect omentin-1 values as well (
21). Lower levels of omentin-1 may be an important factor in the development of postnatal complications such as obesity in newborns with SGA. Lower omentin-1 levels in newborns with SGA could be beneficial in the early detection of obesity and related complications. The exercise, diet, or medical regimens could prevent the development of related complications.
We also examined the socioeconomic status of pregnant women in our study. However, we could not find any difference in terms of educational status and income level between the groups. That might be related to the fact that our study was conducted in a public hospital where people having similar social status often get health care.